Clinical Trial Detail

NCT ID NCT00513474
Title Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Massachusetts General Hospital
Indications

chronic myeloid leukemia

Hodgkin's lymphoma

chronic lymphocytic leukemia

bone marrow cancer

acute lymphocytic leukemia

acute myeloid leukemia

non-Hodgkin lymphoma

Therapies

Rasburicase

Methotrexate

Sirolimus

Cyclosporine

Tacrolimus

Filgrastim

Busulfan + Cyclophosphamide + Etoposide

Age Groups: adult

No variant requirements are available.